Citations

Clear

2303 citation(s) found for "Yu, Edward".

An Unusual Presentation of Copper Metabolism Disorder and a Possible Connection With Niemann-Pick Type C
Goez, Helly , Jacob, Francois D. , Fealey, Robert D., Patterson, Marc C. , Ramaswamy, Vijay , Persad, Rabin, Johnson, Edward S., Yager, Jerome Y. , Patterson, Marc , Ramaswamy, Vijay

Mayo Clinic

Journal of Child Neurology | January 27, 2011 | Volume: 26 | Issue: 4 | Pages: 518-521

10.1177/0883073810383983 | PMID 21273508 Get It

Abnormal copper metabolism has been linked with neurological disorders, such as Wilson and Menkes disease. Another disorder causing symptoms similar to copper metabolism disorder is Niemann-Pick type C. However, a definite pathophysiological connection between Niemann-Pick type C and copper metabolism disorders has never been established. The authors present an adolescent with an unusual presentation of copper deficiency—dysarthria, ataxia, and vertical gaze paresis, without significant cognitive degeneration or pathological magnetic resonance imaging (MRI). The patient was found to carry 2 mutations in the NPC1 gene. A possible link, explaining how copper deficiency might induce the Niemann-Pick phenotype might involve overproduction of cholesterol and inhibition of acid sphingomyelinase. We suggest that copper metabolism disorders be included in the differential diagnosis for ataxia and dysarthria, even in cases with unusual presentations. Moreover, should the connection between copper and Niemann-Pick be validated, screening for copper metabolism disorders may be advisable in Niemann-Pick type C patients and vice-versa.
Myasthenic syndrome caused by plectinopathy
Selcen, Duygu , Juel, Vern C. , Hobson‐Webb, Lisa D., Smith, Edward C. , Stickler, David E., Bite, Anna V., Ohno, Kinji , Engel, Andrew G.

Mayo Clinic

Neurology | January 24, 2011 | Volume: 76 | Issue: 4 | Pages: 327-336

10.1212/wnl.0b013e31820882bd | PMID 21263134 Get It

Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
Abla, Oussama , Weitzman, Sheila, Blay, Jean‐Yves , Abrey, Lauren E. , Neuwelt, Edward A. , Doolittle, Nancy D., Baehring, Joachim M. , Pradhan, Kamnesh R. , Martin, Sheelagh, Guerrera, Michael F., Shah, Shafqat, Ghesquières, Hervé , Silver, Michael, Batchelor, Tracy T. , O’Neill, Brian Patrick , Betensky, Rebecca A. , Blay, Jean-Yves

Mayo Clinic

Clinical Cancer Research | January 12, 2011 | Volume: 17 | Issue: 2 | Pages: 346-352

10.1158/1078-0432.ccr-10-1161 | PMID 21224370 Get It

Abstract Purpose: To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL). Experimental Design: A retrospective series of children and adolescents with PCNSL was assembled from 10 cancer centers in 3 countries. Results: Twenty-nine patients with a median age of 14 years were identified. Sixteen (55%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or greater. Frontline therapy consisted of chemotherapy only in 20 patients (69%), while 9 (31%) had chemotherapy plus cranial radiotherapy. Most patients received methotrexate (MTX)-based regimens. Overall response rate was 86% (complete remission 69%, partial remission 17%). The 2-year progression-free survival (PFS) and overall survival (OS) rates were 61% and 86%, respectively; the 3-year OS was 82%. Univariate analyses were conducted for age (≤14 vs. >14 years), PS (0 or 1 vs. >1), deep brain lesions, MTX dose, primary treatment with chemotherapy alone, intrathecal chemotherapy, and high-dose therapy. Primary treatment with chemotherapy alone was associated with better overall response rates with an odds ratio (OR) of 0.125 (P = 0.02). There was a marginally significant relationship between higher doses of MTX and response (OR = 1.5, P = 0.06). ECOG-PS of 0 to 1 was the only factor associated with better outcome with hazard ratios of 0.136 (P = 0.017) and 0.073 (P = 0.033) for PFS and OS, respectively. Conclusion: This is the largest series collected of pediatric PCNSL. The outcome of children and adolescents seems to be better than in adults. PS of 0 to 1 is associated with better survival. Clin Cancer Res; 17(2); 346–52. ©2011 AACR.
Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer Chemoprevention
Mahoney, Michelle R., Ziegler, Katie L. Allen, Sontag, Stephen J. , Benya, Richard V., Lawson, Michael J. , Weinberg, David S. , Chiorean, Michael , Heigh, Russell I., Levine, Joel B., Della’Zanna, Gary , Rodriguez, Luz M. , Gostout, Christopher J., Mandrekar, Sumithra J. , Smyrk, Thomas C. , Limburg, Paul J. , Schoen, Robert E. , Stoffel, Elena M. , RODRIGUEZ, LUZ MARIA , Richmond, Ellen S.

Mayo Clinic

Cancer Prevention Research | January 6, 2011 | Volume: 4 | Issue: 2 | Pages: 259-269

10.1158/1940-6207.capr-10-0215 | PMID 21209397 Get It

Abstract Sulindac, atorvastatin, or prebiotic dietary fiber may reduce colorectal cancer (CRC) risk. However, clinical trial data are currently limited. We conducted a randomized, phase II chemoprevention trial involving subjects 40 years or older, with previously resected colon cancer or multiple/advanced colorectal adenomas. Magnification chromoendoscopy (MCE) was performed to identify and characterize rectal aberrant crypt foci (ACF); eligibility criteria required five or more rectal ACFs at baseline. Intervention assignments were as follows: (a) atorvastatin 20 mg qd; (b) sulindac 150 mg bid; (c) oligofructose-enriched inulin (as ORAFTI®Synergy1) 6 gm bid; or (d) control (maltodextrin) 6 gm bid, for 6 months. Percent change in rectal ACF number (%ΔACF) within arm was the primary endpoint. Secondary endpoints included changes in proliferation (Ki67) and apoptosis (caspase-3), as measured from normal mucosa biopsy samples. Among 85 eligible randomized subjects, 76 (86%) completed the trial per protocol. The median (range) of rectal ACF was 9 (5–34) and 8 (0–37) at baseline and postintervention, respectively. The median (SD) for %ΔACF was 5.6 (−69% to 143%), −18.6 (−83% to 160%), −3.6 (−88% to 83%), and −10.0 (−100% to 117%) in the atorvastatin, sulindac, ORAFTI®Synergy1 and control arms, respectively. Neither within-arm (P = 0.12–0.59) nor between-arm (P = 0.30–0.92) comparisons of %ΔACF were statistically significant. The active and control interventions also seemed to have similar effects on mucosal proliferation and apoptosis (P > 0.05 for each comparison). Data from this multicenter, phase II trial do not provide convincing evidence of CRC risk reduction from 6-month interventions with atorvastatin, sulindac, or ORAFTI®Synergy1, although statistical power was limited by the relatively small sample size. Cancer Prev Res; 4(2); 259–69. ©2011 AACR.
Type II Transforming Growth Factor-β Receptor Recycling Is Dependent upon the Clathrin Adaptor Protein Dab2
Penheiter, Sumedha G., Singh, Raman Deep , Repellin, Claire E. , Wilkes, Mark C. , Edens, Maryanne, Pagano, Richard E., Leof, Edward B. , Howe, Philip H.

Mayo Clinic

Molecular Biology of the Cell | September 30, 2010 | Volume: 21 | Issue: 22 | Pages: 4009-4019

10.1091/mbc.e09-12-1019 | PMID 20881059 Get It

Transforming growth factor (TGF)-β family proteins form heteromeric complexes with transmembrane serine/threonine kinases referred to as type I and type II receptors. Ligand binding initiates a signaling cascade that generates a variety of cell type-specific phenotypes. Whereas numerous studies have investigated the regulatory activities controlling TGF-β signaling, there is relatively little information addressing the endocytic and trafficking itinerary of TGF-β receptor subunits. In the current study we have investigated the role of the clathrin-associated sorting protein Disabled-2 (Dab2) in TGF-β receptor endocytosis. Although small interfering RNA-mediated Dab2 knockdown had no affect on the internalization of various clathrin-dependent (i.e., TGF-β, low-density lipoprotein, or transferrin) or -independent (i.e., LacCer) cargo, TGF-β receptor recycling was abrogated. Loss of Dab2 resulted in enlarged early endosomal antigen 1-positive endosomes, reflecting the inability of cargo to traffic from the early endosome to the endosomal recycling compartment and, as documented previously, diminished Smad2 phosphorylation. The results support a model whereby Dab2 acts as a multifunctional adaptor in mesenchymal cells required for TGF-β receptor recycling as well as Smad2 phosphorylation.
ERBB Receptor Activation Is Required for Profibrotic Responses to Transforming Growth Factor β
Andrianifahanana, Mahefatiana, Wilkes, Mark C. , Repellin, Claire E. , Edens, Maryanne, Rahimi, Rod A. , Leof, Edward B. , Kottom, Theodore J.

Mayo Clinic

Cancer Research | September 14, 2010 | Volume: 70 | Issue: 19 | Pages: 7421-7430

10.1158/0008-5472.can-10-0232 | PMID 20841477 Get It

Abstract Engagement of the transforming growth factor-β (TGF-β) receptor complex activates multiple signaling pathways that play crucial roles in both health and disease. TGF-β is a key regulator of fibrogenesis and cancer-associated desmoplasia; however, its exact mode of action in these pathologic processes has remained poorly defined. Here, we report a novel mechanism whereby signaling via members of the ERBB or epidermal growth factor family of receptors serves as a central requirement for the biological responses of fibroblasts to TGF-β. We show that TGF-β triggers upregulation of ERBB ligands and activation of cognate receptors via the canonical SMAD pathway in fibroblasts. Interestingly, activation of ERBB is commonly observed in a subset of fibroblast but not epithelial cells from different species, indicating cell type specificity. Moreover, using genetic and pharmacologic approaches, we show that ERBB activation by TGF-β is essential for the induction of fibroblast cell morphologic transformation and anchorage-independent growth. Together, these results uncover important aspects of TGF-β signaling that highlight the role of ERBB ligands/receptors as critical mediators in fibroblast responses to this pleiotropic cytokine. Cancer Res; 70(19); 7421–30. ©2010 AACR.
Cystic Fibrosis Gene Mutation in Two Sisters with Mild Disease and Normal Sweat Electrolyte Levels
Strong, Theresa V. , Smit, Lisa S., Turpin, Steven V., Cole, Jeffery L., Hon, Catherine Tom, Markiewicz, D., Petty, Thomas L., Craig, Michael W. Millar, Rosenow, Edward C., Tsui, Lap‐Chee, Iannuzzi, Michael C., Knowles, Michael R. , Collins, Francis S.

Mayo Clinic

New England Journal of Medicine | July 28, 2010 | Volume: 325 | Issue: 23 | Pages: 1630-1634

10.1056/nejm199112053252307 | PMID 1944451 Get It

O2‐03‐01: Insight into the mechanism of gamma‐secretase cleavage: Juxtamembrane amino acids are key to the length of secreted amyloid beta peptide
Kukar, Thomas , Ladd, Thomas B., Robertson, Paul , Jansen‐West, Karen , Eggert, Simone , Koo, Edward H. , Golde, Todd E. , Moore, Brenda D.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2010.05.314 Get It

Estrogen Receptor Gene Expression in Craniopharyngiomas
Thapar, Kamal, Ştefăneanu, Lucia, Kovács, Kálmán, Scheithauer, Bernd W., Lloyd, Ricardo V., Laws, Edward R. , Müller, Paul J.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 35 | Issue: 6 | Pages: 1012-1017

10.1227/00006123-199412000-00002 | PMID 7885545 Get It